<p><strong>FINAL PROGRAMME </strong></p><p><strong>Friday, 12 June 2015 </strong></p><p>8.00-9.00 9.00-9.30 <br>Registration Welcome Address/Opening ceremony </p><p>Chairs: S. Cicėnas (Vilnius, Lithuania) </p><p><em>Minister of health of the Republic of Lithuania (Vilnius, Lithuania) Rector of Vilnius University (Vilnius, Lithuania) Dean of the Faculty of Medicine Vilnius University (Vilnius, Lithuania) Director of the Nacional Cancer Institute (Vilnius, Lithuania) </em></p><p></p><ul style="display: flex;"><li style="flex:1">SESSION I </li><li style="flex:1">9.30 – 11.00 </li></ul><p>Chairs: J. Niklinski (Bialystok, Poland), K. Sužiedėlis (Vilnius, Lithuania) Bialystok Medical Academy – Research Group (Bialystok, Poland) Chairs: Prof. Jacek Niklinski, Prof. Lech Chyczewski <br>9.30-11.00 </p><p></p><p>Immune system and lung cancer: friends or foes? </p><p><em>M. Moniuszko </em></p><p>Science fiction or science reality - microRNA replacement therapy </p><p><em>Anna Rusek </em></p><p>The role of transcription factor Sox2 in cancer biology </p><p><em>A. Eljaszewicz </em></p><p></p><p>Recent guidelines for the diagnosis of non-small cell lung cancer- diagnostic challenges and problems </p><p><em>J. Reszec </em></p><p>Metabolomic profiling of non-small cell lung cancer </p><p><em>J. Kisluk </em></p><p></p><ul style="display: flex;"><li style="flex:1">11.00 - 11.30 </li><li style="flex:1">Lung cancer in women and never smokers </li></ul><p></p><p><em>S. Novello (Turin, Italy) </em></p><p></p><ul style="display: flex;"><li style="flex:1">11.30 - 12.00 </li><li style="flex:1">Coffee break </li></ul><p></p><ul style="display: flex;"><li style="flex:1">12.00 –13.00 </li><li style="flex:1">AstraZeneca Satellite Symposium </li></ul><p></p><p>Chair: S. Cicėnas <em>(Vilnius, Lithuania) </em></p><p></p><ul style="display: flex;"><li style="flex:1">Lunch </li><li style="flex:1">13.00-14.00 </li></ul><p>14.00 – 16.40 Scientific&nbsp;session II <br>Chairs: R. Pirker (Vienna, Austria), E. Danila (Vilnius, Lithuania). <br>14.00-14.40 </p><p>14.40-15.00 15.00-15.20 15.20-15.40 15.40-16.00 16.00-16.20 16.20-16.40 <br>Bevacizumab in&nbsp;treatment of NSCLC: preferred chemo partners </p><p><em>F. De Marinis (Milan, Italy) </em></p><p>Lung Cancer Screening – Radiological Opportunities and Challenges </p><p><em>S. Sudarski (Mannheim, Germany) </em></p><p>Tobacco control strategies </p><p><em>M. Neuberger (Vienna, Austria) </em></p><p>Lung cancer screening by spiral CT </p><p><em>M. Silva (Milano, Italy) </em></p><p>Biomarkers for chemotherapy in NSCLC </p><p><em>J.B. Soerensen (Copenhagen, Denmark) </em></p><p>Adjuvant therapy of completely resected NSCLC: current status and perspectives </p><p><em>R. Pirker (Vienna, Austria) </em></p><p>The application of electronic odour identification system in disease diagnosis: possibilities and limitations </p><p><em>A. Šetkus (Vilnius, Lithuania) </em></p><p>16.40 – 17.00 Coffee&nbsp;break 17.00 – 19.00 Scientific&nbsp;session III <br>Chairs: Ch. Manegold (Mannheim, Germany), L. Pilz (Mannheim, Germany) </p><ul style="display: flex;"><li style="flex:1">17.00-17.40 </li><li style="flex:1">Mechanisms of resistance to EGFR TKI and treatment strategies </li></ul><p></p><p><em>F. De Marinis (Milan, Italy) </em></p><p></p><ul style="display: flex;"><li style="flex:1">17.40-18.00 </li><li style="flex:1">Necitumumab and ramucirumab: Promising monoclonal antibodies in NSCLC </li></ul><p></p><p><em>Ch. Manegold (Mannheim, Germany) </em></p><p>18.00– 18.20 New&nbsp;concepts for study design in lung cancer </p><p><em>L. Pilz (Mannheim, Germany) </em></p><p>18.20-18.40 18.40-19.00 <br>Modern trends in surgery and multimodality treatment of thymic tumours </p><p><em>O. Pikin (Moscow, Russian Federation) </em></p><p>Molecular testing - expanding therapeutic options for NSCLC patients after introducing of afatinib </p><p><em>P. Krawczyk ( Lublin, Poland ) </em></p><p>19.00 – 19.20 Treatment&nbsp;of NSLC&nbsp;after progession </p><p><em>O.-T. Brustugum (Oslo, Norway) </em></p><p>Dinner (hotel restaurant “Sezonai” ground floor) </p><p>19:30 </p><p><strong>Saturday, 13 June 2015 </strong></p><p></p><ul style="display: flex;"><li style="flex:1">8.00-9.00 </li><li style="flex:1">Registration </li></ul><p></p><ul style="display: flex;"><li style="flex:1">9.00- 10.00 </li><li style="flex:1">Scientific session IV - Case reports </li></ul><p>Chairs: O. Pikin (Moscow, Russian Federation), E. Sigal (Kazan, Russian Federation) Combined and radical treatment for initially inoperable NSCLC </p><p><em>A. Akopov (Petersburg, Russian Federation) </em></p><p>Making a diagnosis: the challenging case from pathologist </p><p><em>A. Šimbelytė (Vilnius, Lithuania) </em></p><p>Pharyngo-gastro anastomosis after upper part of esophageal cancer resections </p><p><em>M. Burmistrov, A. Rudik (Kazan, Russian Federation) </em></p><p>Coffee Break <br>9.00-9.20 <br>9.20 – 9.40 <br>9.40 – 10.00 10.00-10.20 </p><ul style="display: flex;"><li style="flex:1">10.20- 11:20 </li><li style="flex:1">Scientific session V - Case reports </li></ul><p>Chairs: M. Burmistrov (Kazan, Russian Federation), S. Cicėnas (Vilnius, Lithuania), V. Zharkov (Minsk, Belarus) <br>10.20-10.40 </p><p>10.40-11.00 11.00-11.20 11.20- 11.40 <br>International VTE Clinical Guidelines in Cancer </p><p><em>D. Inčiūra (Kaunas, Lithuania) </em></p><p>Radical treatment of lung cancer patient with massive invasion of left atrium </p><p><em>V. Zharkov, S. Yeskov (Minsk, Belarus) </em></p><p>Long term survival in metastatic NSCLC </p><p><em>D. Vaitiekus (Kaunas, Lithuania) </em></p><p>Closing remarks </p><p>Chairs: Ch. Manegold (Mannheim, Germany), J. Niklinski (Bialystok, Poland), S. Cicėnas (Vilnius, </p><p>Lithuania) </p>